CD19 and B-cell acute lymphoblastic leukemia: Although less than 50% of pediatric patients who receive tisagenlecleucel achieve long-term event-free survival (EFS) (87), the response rate of CD19 CAR T cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) is remarkable.